Lupin receives U.S. FDA's approval for Lenalidomide Capsules

17 Sep 2025 Evaluate

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg. Lenalidomide Capsules are bioequivalent to Revlimid Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, of Bristol-Myers Squibb Company. This product will be manufactured at company’s Pithampur facility in India.

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma (MM), in combination with dexamethasone; MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT); Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg (RLD Revlimid) had estimated annual sales of $7,511 million in the U.S. (IQVIA MAT July 2025).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2102.50 10.55 (0.50%)
05-Dec-2025 15:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.00
Dr. Reddys Lab 1276.05
Cipla 1521.20
Zydus Lifesciences 931.85
Lupin 2102.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×